naquotinib mesilate + Erlotinib + Gefitinib
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer (NSCLC)
Conditions
Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Feb 11, 2016 → Dec 21, 2017
NCT ID
NCT02588261About naquotinib mesilate + Erlotinib + Gefitinib
naquotinib mesilate + Erlotinib + Gefitinib is a phase 3 stage product being developed by Astellas Pharma for Non-small Cell Lung Cancer (NSCLC). The current trial status is terminated. This product is registered under clinical trial identifier NCT02588261. Target conditions include Non-small Cell Lung Cancer (NSCLC).
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer (NSCLC) were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02588261 | Phase 3 | Terminated |
Competing Products
20 competing products in Non-small Cell Lung Cancer (NSCLC)